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Activation of peroxisome proliferator-activated receptor gamma (PPARg) has been linked to induction of differentiation, cell
growth inhibition and apoptosis in several types of human cancer. However, the possible effects of PPARg agonists on human
oral squamous cell carcinoma have not yet been reported. In this study, treatment with 15-deoxy-D
12,14-PGJ2 (15-PGJ2), a
natural PPARg ligand, induced a signiﬁcant reduction of oral squamous cell carcinoma cell growth, which was mainly attributed
to upregulation of apoptosis. Interestingly, rosiglitazone and ciglitazone, two members of the thiazolidinedione family of PPARg
activators, did not exert a growth inhibitory effect. Given the critical role that the oncogene signal transducer and activator of
transcription 3 (Stat3) plays in head and neck carcinogenesis, its potential regulation by PPARg ligands was also examined.
Treatment of oral squamous cell carcinoma cells with 15-PGJ2 induced an initial reduction and eventual elimination of both
phosphorylated and unphosphorylated Stat3 protein levels. In contrast, other PPARg did not induce similar effects. Our results
provide the ﬁrst evidence of signiﬁcant antineoplastic effects of 15-PGJ2 on human oral squamous cell carcinoma cells, which
may be related to downmodulation of Stat3 and are at least partly mediated through PPARg-independent events.
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Peroxisome proliferator-activated receptors (PPARs) are members
of the nuclear hormone receptor family, which function as
ligand-dependent, sequence-speciﬁc activators of transcription.
The PPAR family consists of three distinct molecules, termed a,
d (b, FFAR or NUC-1), and g, encoded by separate genes and char-
acterised by speciﬁc tissue and developmental distribution patterns
(Mangelsdorf et al, 1995; Lemberger et al, 1996; Gelman et al, 1999;
Kersten et al, 2000). A variety of natural and pharmacological
ligands, including prostaglandins, the ﬁbrate class of hypolipidae-
mic drugs, the anti-diabetic drugs thiazolidinediones, and certain
non-steroidal anti-inﬂammatory drugs, are able to bind to and
activate PPARs (Forman et al, 1995, 1997; Yu et al, 1995; Lehmann
et al, 1997). Upon activation, PPARs heterodimerise with the reti-
noic X receptor (RXR) and bind to peroxisome proliferator
response elements (PPREs), located in the promoter region of
target genes, driving their transcription (Mangelsdorf et al, 1995).
PPARs were initially described as molecular targets for
compounds that induce peroxisome proliferation (Issemann and
Green, 1990). However, shortly after their discovery, it became
apparent that the physiologic role of PPARs extends far beyond
peroxisome proliferation, involving such diverse processes as lipid
homeostasis, insulin sensitisation, inﬂammation, and cell prolifera-
tion (Lemberger et al, 1996; Gelman et al, 1999; Kersten et al,
2000). Today, PPARs are recognised as key regulators of lipid
homeostasis, playing fundamental roles in adipogenesis and fat
catabolism (Lemberger et al, 1996; Kersten et al, 2000). Potential
roles of PPARs in the treatment of diabetes mellitus (Vamecq
and Latruffe, 1999), in inﬂammation control (Gelman et al,
1999), and in the regulation of atherosclerosis and thrombosis
(Vamecq and Latruffe, 1999; Duez et al, 2001) have also been
described.
The role of PPARg in the acquisition of an adipocyte phenotype,
through the control of the expression of genes that promote cell
cycle withdrawal, drive differentiation and induce apoptosis (Shao
and Lazar, 1997; Debril et al, 2001), prompted many investigators
to study the potential function of PPARg in neoplasia. Multiple
lines of evidence suggest that PPARs, especially PPARg, play an
important role in modulating cell proliferation and tumour growth
(Gelman et al, 1999; Kersten et al, 2000; Debril et al, 2001; Park et
al, 2001; Rosen and Spiegelman, 2001). Ligand-induced PPARg
activation has been shown to promote differentiation and to
induce cell growth inhibition and apoptosis in several types of
human cancer, including colon cancer (Sarraf et al, 1998; Kitamura
et al, 1999; Yang and Frucht, 2001), breast cancer (Elstner et al,
1998; Mueller et al, 1998), lung cancer (Chang and Szabo, 2000),
prostate cancer (Kubota et al, 1998; Butler et al, 2000), gastric
cancer (Sato et al, 2000), liposarcoma (Tontonoz et al, 1997;
Demetri et al, 1999), and leukaemia (Sugimura et al, 1999). Histo-
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induce tumour cell differentiation in patients with advanced lipo-
sarcoma (Demetri et al, 1999). Consistent with its possible
function as a tumour suppressor gene, PPARg has been reported
to be functionally mutated in sporadic cases of colon cancer (Sarraf
et al, 1999); nonetheless, the overall incidence of PPARg mutations
in human malignancies seems to be very rare (Ikezoe et al, 2001).
We recently showed that the non-steroidal anti-inﬂammatory
drug (NSAID) sulindac induces cell growth inhibition and apopto-
sis in human oral squamous cell carcinoma (SCCa) cells,
accompanied by upregulation of the mRNA and protein expression
of PPARg. Treatment with antisense PPARg oligonucleotides abol-
ished the cell growth inhibitory effect of the NSAID sulindac.
These results suggest that upregulation of PPARg expression and
activation may be, at least partially, responsible for sulindac’s anti-
neoplastic effect (Nikitakis et al, 2002a). However, it is unknown
whether ligand-induced PPARg activation may alter the cell growth
of oral SCCa. Here, we assessed the effects that the natural PPARg
ligand 15-deoxy-D
12,14-PGJ2 (15-PGJ2) and the synthetic PPARg
ligands rosiglitazone and cigliatazone have on cell growth, apopto-
sis and cell proliferation in oral SCCa cells. Moreover, we explored
the possibility that PPARg activation may affect the expression and
activation of Stat3, an oncogene that plays a critical role in head
and neck carcinogenesis (Grandis et al, 1998, 2000; Bromberg et
al, 1999; Bowman et al, 2000) and is downregulated by sulindac
in oral SCCa cells (Nikitakis et al, 2002b).
MATERIALS AND METHODS
Cell lines and cell culture
Experiments were performed using established cell lines of human
oral SCCa (SCC-4, -9, -15 and -25) obtained from the American
Type Culture Collection (ATCC) (Manassas, VA, USA). Cells were
cultured in a 1:1 mixture of Ham’s F12 and Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) containing 10% foetal bovine serum
(FBS), 100 units of penicillin, 100 mgm l
71 streptomycin and
0.4 mgm l
71 hydrocortisone (Sigma Chemical Co., St. Louis, MO,
USA) at 378C in a 5% CO2 air atmosphere. Cells were subcultured
by disaggregation with trypsin (0.1%)–EDTA (0.01%) in phos-
phate buffered saline (PBS) at pH 7.5.
Quantitative reverse transcriptase polymerase
chain reaction
To estimate the mRNA levels of PPARg, real-time quantitative
reverse transcriptase polymerase chain reaction (RT–PCR) was
performed using a PE Applied Biosystems protocols. Total RNA
was isolated using the TRIZOL Reagent (BRL/Life Technologies)
and the concentration of RNA was determined using spectrophoto-
metry. The forward and reverse PPARg primers were selected using
Primer Express software (PE Applied Biosysystems, Foster City,
CA, USA) as follows: 5'-TATCGACCAGCTGAATCCAGAG-3'
(forward) and 5'-TCGCCTTTGCTTTGGTCA-3' (reverse). For the
PCR reaction, a SYBR
1 Green PCR kit (PE Applied Biosystems)
was used and the analyses were performed in triplicate. For each
well, 5 mlo f2 5n M RNA extract were added to a solution consist-
ing of: 25 ml Master Mix solution (SYBR Green PCR Buffer,
AmpErase
1 UNG, AmpliTaq Gold
1 DNA Polymerase, dATP,
dCTP, dGTP, dUTP and 25 mM MgCl2), 1 ml of RNAse inhibitor,
0.25 ml of reverse transcriptase (MultiScribe), 1 ml of each primer
and 16.75 ml of water. The ampliﬁcation process included 30 min
at 488C, 10 min at 958C, followed by 40 cycles of 15 s at 958C
and 1 min at 608C. Thermal cycling and ﬂuorescence detection
were performed using an ABI 5700 Prism (PE Applied Biosystems).
Relative quantitation of the signal of PPARg mRNA followed. The
signal of the target mRNA was normalised by comparison with the
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA signal. The normalised amount of PPARg mRNA
present in each cell line was calculated by arbitrarily designating
SCC25 cells as a calibrator using a comparative Ct method follow-
ing PE Applied Biosystems protocols.
Immunocytochemistry
Cells were plated on chamber slides (LabTech Nalge/Nunc) at a
density of 5610
4 cells/chamber and were allowed to grow until
almost conﬂuent. The cells were then rinsed with Hanks’ balanced
salt solution (HBSS) and ﬁxed with 95% ethanol for 20 min.
PPARg protein expression was ascertained by immunocytochemical
analysis (Santa Cruz Biotechnology, Santa Cruz, CA, USA, sc-1984)
1:50. The presence of antibody staining was determined after incu-
bation of the sections with a secondary antibody (Biogenex, San
Ramon, CA, USA, HK327-UG) 1:20, followed by the application
of StrepABComplex/HRP (Dako, Carpinteria, CA, USA, K0377),
and diaminobenzidine (DAB). The slides were counterstained with
Harris’s haematoxylin. The intensity of the immunostaining was
classiﬁed as: 0 (negative), 1 (weakly positive), 2 (moderately posi-
tive), and 3 (strongly positive).
Immunohistochemistry
Ten cases of oral squamous cell carcinoma were randomly selected
from the ﬁles of the Department of Diagnostic Sciences and
Pathology. No patients were identiﬁed for these studies. The histo-
logical slides were reviewed to conﬁrm diagnosis.
Five-micron sections of parafﬁn-embedded tissue were mounted
on glass slides, deparafﬁnised and rehydrated. An antigen retrieval
procedure was performed by placing the sections in Citra-solution
(HK086-9K; Biogenex, San Ramon, CA, USA) inside a plastic pres-
sure cooker, which was positioned in a microwave oven (Kenmore;
Sears, Chicago, IL, USA). The specimens were treated by two
cycles, 15 min each, at a high level and at level 4, respectively.
Endogenous peroxidase activity was blocked with 3% hydrogen
peroxide and non-speciﬁc protein was blocked with a universal
blocking reagent (HK085-5K; Biogenex). Sections were then treated
with PPARg antibody, followed by incubation with secondary anti-
body, application of StrepABComplex/HRP and staining with
diaminobenzidine (DAB) and Harris haematoxylin, using the
aforementioned reagents and dilutions.
Cell growth inhibition
Cells were plated on 24-well plates at a density of 5610
4 cells
well
71. After 24 h, the growth medium was supplemented with
DMSO at a concentration of 0.1% or with either one of the follow-
ing: 15-deoxy-D
12,14-Prostaglandin J2 (15-PGJ2) (Cayman
Chemical, Ann Arbor, MI, USA) at concentrations of 10 or
20 mM, rosiglitazone (Cayman Chemical) at concentrations of 25
or 50 mM, and ciglitazone (Biomol, Plymouth Meeting, PA, USA)
at concentrations of 25 or 50 mM. All three compounds were
dissolved in 100% DMSO, so that the ﬁnal concentration of
DMSO did not exceed 0.1%. Following incubation for 24, 48 or
72 h, either treated or untreated cells were removed enzymatically
and counted using a Coulter Counter (Coulter Model ZI, Coulter
Corporation, Miami, FL, USA). The per cent of growth was deter-
mined setting as 100% the growth of cells treated only with the
vehicle (0.1% DMSO). All analyses were performed in triplicate.
Cell cycle analysis
Cells were treated either with the vehicle alone (0.1% DMSO) or
with 10 or 20 mM of 15-PGJ2 dissolved in 100% DMSO for 72 h.
Cells were dissociated using trypsin-EDTA in PBS, pelleted and
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in distilled water were added dropwise. The cells were incubated at
48C for 30 min and then were centrifuged at 2500 g for 5 min. The
pellet was resuspended in 200 ml of two-fold propidium iodide (PI)
dye and 200 ml of RNAse A (2 mg ml
71) and the tubes were incu-
bated for 45 min in the dark at 48C. Cells were ﬁltered through
nylon mesh prior to analysis. The DNA content of cells stained
with PI and was measured with a FACScan instrument using Cell
Quest software (Becton/Dickinson). To determine the proportion
of cells in G0-G1, S and G2-M, cell cycle analysis of DNA histo-
grams was performed using ModFitLTV2.0 (PMac). All analyses
were performed in duplicate.
Apoptosis analysis
Apoptosis was assessed by Annexin V-FITC staining (BD Bio-
sciences). In essence, cells were treated either with the vehicle alone
(0.1% DMSO) or with 10 or 20 mM of 15-PGJ2 dissolved in 100%
DMSO for 72 h. Then, cells were washed twice with cold PBS and
resuspended in 16 binding buffer at a concentration of
1610
6 cell ml
71. One hundred microlitres of the solution were
transferred to a 5 ml culture tube and 5 ml of Annexin V-FITC
and 5 ml of PI were added. The mixture was gently vortexed and
incubated for 15 min in the dark. Four hundred microlitres of
16 binding buffer were added to each tube and FACScan analysis
of the samples was performed within 1 h using a FACS scan
equipped with Cell Quest software (Becton Dickenson). The
following controls were used to set up compensation and quad-
rants: (1) unstained cells, (2) cells stained with Annexin V-FITC
alone, and (3) cells stained with PI alone. The percentage of cells
that have been induced to undergo apoptosis was determined by
subtracting the percentage of apoptotic cells in the untreated popu-
lation from the percentage of apoptotic cells in the treated
population. All analyses were performed in duplicate.
Protein lysate preparation and Western blotting
Cells were plated on 6-well plates at a density of 5610
4 cells
well
71 and were allowed to grow to 80% conﬂuency. Then, 15-
PGJ2 at 20 mM concentration, rosiglitazone at 50 mM concentration,
or ciglitazone at 50 mM concentration, was added to the medium.
All three compounds were dissolved in 100% DMSO, so that the
ﬁnal concentration of DMSO did not exceed 0.1%. Following incu-
bation for various time periods, the cells were washed twice with
cold PBS, lysed in RIPA buffer (50 mM Tris (pH 7.4), 150 mM
NaCl, 1% Triton X-100, 1% deoxycholic acid, sodium salt, 0.1%
sodium dodecyl sulphate (SDS), 100 mgm l
71 phenylmethylsulpho-
nyl ﬂuoride, 1 mgm l
71 aprotinin, 1 mM dithiothreitol, and 1 mM
sodium orthovanadate) for 10 min, and scraped. The extracts were
centrifuged at 40000 g for 15 min at 48C. Protein concentrations
were measured and equalised using Bio-Rad protein assay (Bio-
Rad Laboratories, Richmond, CA, USA) according to the manufac-
turer’s instructions.
Western blot analysis was performed using phospho-Stat3 (Tyr
705) antibody (1:500 dilution) (Cell Signaling Technology, Beverly,
MA, USA) according to the manufacturer’s instructions. Blots were
stripped (20 mM dithiothreitol, 2% SDS, and 67.5 mM Tris-HCl
(pH 6.7)) and then reprobed sequentially with Stat3 (Tyr 705)
antibody (1:1000 dilution) (Cell Signaling Technology, Beverly,
MA, USA) and with actin antibody (1:500 dilution) (Sigma, Saint
Louis, MO, USA).
Statistical analysis
Data were submitted to an analysis of variance with repeated
measures (time and dosage), using Newman–Keuls post hoc
comparisons where appropriate (Statistica for Windows, StatSoft,
Inc., Tulsa, OK, USA). An alpha value of P40.05 was used in
all models and post hoc comparisons.
RESULTS
Expression of PPARg in oral SCCa cell lines and tissues
Quantitative RT–PCR analysis showed mRNA expression for
PPARg in all four oral SCCa cell lines. The lowest levels of PPARg
mRNA were expressed in SCC25 and the highest in SCC9 (Table
1). Protein expression of PPARg was detected by means of immu-
nocytochemistry; PPARg immunostaining, primarily in a
cytoplasmic location, was evident in all four oral SCCa cell lines
(Figure 1A,B). Immunohistochemistry for PPARg in tumour speci-
mens of patients with oral SCCa revealed PPARg production by the
tumour cells, which was limited to the well-differentiated areas of
the tumours (Figure 1C).
Effect of PPARg agonists on cell growth inhibition
Oral SCC25 cells treated with 10 or 20 mM of 15-PGJ2 exhibited
reduction in cell growth (Figure 2); similar results were obtained
from the other oral SCCa cell lines. Combining the results from
all four cell lines, a signiﬁcant main effect for time (F2,6=20.6,
P40.01) and interaction of time vs dosage (F4,12=17.4,
P40.0001) was observed, reﬂecting that increases in dosage and
time of treatment were associated with decreases in cell growth.
In contrast, treatment with rosiglitazone or ciglitazone did not
induce signiﬁcant cell growth inhibition in any of the tested cell
lines (P40.05), even when the highest dosage of treatment (i.e.
50 mM) for the longest duration (i.e. 72 h) was employed (Figure
2C).
Effect of 15-deoxy-D
12,14-PGJ2 on apoptosis and cell
proliferation
We tested next whether the cell growth inhibition induced by 15-
PGJ2 was due to alterations in apoptosis or cell proliferation rates.
Treatment of oral SCCa cells with 10 or 20 mM of 15-PGJ2 did
not signiﬁcantly affect the percentage of cells in the S phase of
the cell cycle, which remained stable or was only slightly increased;
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a
Cell line Relative PPARg mRNA levels
b
SCC4 1.23 (1.03–1.47)
SCC9 3.27 (2.11–5.06)
SCC15 1.56 (0.93–2.60)
SCC25 1.00 (0.79–1.27)
aResults were obtained by real-time quantitative RT-PCR;
bAll cell lines were
compared to SCC25, whose level of PPARg mRNA expression was set as 1.
Table 2 Cell cycle proﬁles of oral SCC25 and SCC9 cells treated with
20 mM of 15-PGJ2 or the vehicle alone (0.1% DMSO)
Cell line Treatment G1 S G2
SCC25 DMSO 49.51%+3.44 33.11%+2.55 17.38%+0.90
15-PGJ2 36.89%+2.96 33.97%+7.85 29.14%+4.90
5CC9 DMSO 57.10%+0.13 14.70%+1.23 28.20%+1.31
15-PGJ2 31.95%+2.46 20.79%+3.67 47.26%+1.87
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the cell cycle was observed, accompanied by a corresponding
reduction of cells in the G1 phase (Table 2). These results indicate
a relative accumulation of cells in the G2 phase, which may inter-
fere with cell cycle progression. On the other hand, signiﬁcant 5–
8-fold increases in the levels of apoptosis resulted following treat-
ment with 15-deoxy-D
12,14-PGJ2 for 72 h at concentrations
ranging from 10 to 20 mM (F2,4=9.5, P40.05) (Figure 3).
Effects of PPAR agonists on Stat3 phosphorylation and
expression
Because of the critical role of Stat3 in head and neck carcinogenesis
(Grandis et al, 1998, 2000) and our recent demonstration of sulin-
dac-mediated downmodulation of Stat3 in oral SCCa (Nikitakis et
al, 2002b), we explored the hypothesis that ligand-mediated PPARg
activation causes changes in Stat3 expression and activation.
Forty-ﬁve minutes of treatment with 20 mM of 15-PGJ2 resulted
in a signiﬁcant reduction of phosphorylated Stat3 in SCC9 cells.
Longer treatment, up to 9 h, did not induce further reduction in
phosphorylated Stat3 levels. In contrast, phosphorylated Stat3 levels
were eliminated after 24, 48 or 72 h of treatment with 20 mM of 15-
deoxy-PGJ2 (Figure 4A). Stat3 protein expression levels in SCC9
cells also exhibited a small decrease after 45 min of treatment with
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Figure 1 (A, B) Immunocytochemical detection of PPARg protein
expression in oral SCCa cells (A, SCC25; B, SCC9). (C) Immunohisto-
chemical detection of PPARg in specimens of oral SCCa; immunostaining
was limited to the well-differentiated areas of the tumours.
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Figure 2 (A, B) Effect of 15-deoxy-D
12,14-PGJ2 on growth of oral
SCC25 cells. The cells were treated with 0.1% DMSO, 10 mM 15-deoxy-
PGJ2 or 20 mM 15-deoxy-PGJ2 for various periods of time (24, 48, or
72 h). In (A), the real number of cells is depicted, while in (B), the per cent
of cell growth is shown, after setting the growth of cells treated only with
the vehicle as 100%. A statistically signiﬁcant reduction of cell growth was
observed. Similar results were obtained from the other oral SCCa cell lines
tested. (C) Effect of rosiglitazone (ROSI), ciglitazone (CIGL) and 15-deoxy-
D
12,14-PGJ2 on growth of oral SCC9 cells. The cells were treated with 0.1%
DMSO, 50 mM rosiglitazone, 50 mM ciglitazone or 20 mM of 15-deoxy-PGJ2
for 72 h. Only 15-PGJ2 induced a signiﬁcant cell growth inhibition. All
tested oral SCCa cell lines gave similar results.
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Stat3 could not account for the reduction in phosphorylated levels
of this protein. Stat3 protein levels were not further reduced as a
result of longer, up to 24 h, treatment. However, 48 h of treatment
induced further signiﬁcant reduction of Stat3 expression, which
was eliminated after 72 h of treatment (Figure 4A). In accordance
with the aforementioned results, phosphorylated Stat3 levels were
eliminated and Stat3 protein expression levels were either elim-
inated or severely reduced by 72 h of 15-deoxy-PGJ2 treatment
with 20 mM in all tested cell lines (Figure 4B). These effects could
not be attributed to a nonspeciﬁc reduction of protein expression,
as the protein expression levels of actin were not signiﬁcantly
affected by treatment (Figure 4A,B). On the contrary, treatments
with rosiglitazone or ciglitazone at 50 mM concentrations failed to
affect the phosphorylation or expression of Stat3 (Figure 4B).
Notably, no changes in PPARg protein expression were induced
by either 15-deoxy-PGJ2 or thiazolidinediones (Data not shown).
DISCUSSION
The capacity of PPARg to promote differentiation, cell cycle with-
drawal and apoptosis has encouraged extensive investigation of its
potential anticancer activity in multiple types of human cancer (see
Introduction). We recently showed that NSAID sulindac upregu-
lates PPARg expression and activity and relies on PPARg
availability for its antineoplastic activities on oral SCCa (Nikitakis
et al, 2002a). These observations prompted us to investigate the
possibility that oral SCCa cells are also responsive to treatment
with direct PPARg ligands.
15-PGJ2, a natural PPARg ligand, exerted a statistically signiﬁ-
cant growth inhibitory effect on oral SCCa cells. Signiﬁcant
increases in the levels of apoptosis were observed, suggesting that
15-PGJ2 cell growth inhibitory effect is primarily mediated through
induction of apoptosis. Nonetheless, accumulation of cells in the
G2 phase of the cell cycle was also noted, supporting the concept
that interference of 15-PGJ2 with cell cycle progression may also
contribute to its activity. In contrast, the well-characterised PPARg
ligands rosiglitazone and ciglitazone did not inhibit the cell growth
of oral SCCa cells, implying that PPARg activation is not sufﬁcient
for inducing antineoplastic effects on oral SCCa cells. These results
raise the possibility that the antineoplastic properties of 15-PGJ2
are, at least partially, mediated through PPARg-independent
mechanisms.
PPARg-independent effects of 15-PGJ2 have been previously
reported in other systems, including chondrocytes, myoﬁbroblasts,
mesangial cells, inﬂammatory cells and cells of the nervous system
(Petrova et al, 1999; Castrillo et al, 2000; Rossi et al, 2000; Straus et
al, 2000; Boyault et al, 2001; Li et al, 2001; Janabi, 2002; Ward et
al, 2002). Several mechanisms have been implicated as responsible
for the effects of 15-PGJ2 on these cells and may also partly explain
its antineoplastic properties. Negative regulation of the NF-kB
pathway through inhibition of IkB kinase (IKK) and abrogation
of the DNA binding ability of NF-kB, has emerged as a major
pathway of PPARg-independent 15-PGJ2 activity (Petrova et al,
1999; Castrillo et al, 2000; Rossi et al, 2000; Straus et al, 2000;
Boyault et al, 2001; Janabi, 2002;). 15-PGJ2-mediated NF-kB inhi-
bition has been linked to downregulation of inducible nitric oxide
synthase (iNOS) and abrogation of cyclooxygenase-2 (COX-2)
transactivation (Petrova et al, 1999; Castrillo et al, 2000; Rossi et
al, 2000; Straus et al, 2000; Boyault et al, 2001; Janabi, 2002). Simi-
larly, Ward et al (2002) recently showed that 15-PGJ2 exploits
PPARg-independent inhibition of NF-kB activation to induce
caspase-dependent apoptosis in granulocytes. Other mediators that
have been implicated in PPARg-independent properties of 15-PGJ2
and can potentially have a similar function in cancer cells include
AP-1 (Boyault et al, 2001), MAP kinase (Harris et al, 2002; Lennon
et al, 2002), and reactive oxygen species (Li et al, 2001; Lennon et
al, 2002). The latter has been shown to act as intermediates for the
induction of apoptosis caused by 15-PGJ2 in human myoﬁbroblasts
(Li et al, 2001). Identiﬁcation of the molecular pathways that
mediate the PPARg-independent antineoplastic effects of 15-PGJ2
should be thoroughly addressed in future studies. In this respect,
the recent observations of Clay et al (2001) that early de novo gene
expression is necessary for 15-PGJ2-induced apoptosis in breast
cancer cells may be of particular relevance.
Although our data strongly support the existence of PPARg-
independent effects of 15-PGJ2 on oral SCCa cells, recruitment of
PPARg-mediated pathways cannot be ruled out. However, the
precise molecular mechanisms that are responsible for the antineo-
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
30
25
20
15
10
5
0
%
 
A
p
o
p
t
o
s
i
s
SCC25 SCC9
DMSO
PGJ2
Figure 3 Effect of 15-deoxy-D
12,14-PGJ2 on levels of apoptosis of oral
SCC25 and SCC9 cells treated with 0.1% DMSO or 20 mM of the drug
for 72 h. Treatment with 15-deoxy-D
12,14-PGJ2 resulted in a statistically
signiﬁcant increase in apoptosis compared to DMSO-treated control cells.
Similar results were obtained from the other oral SCCa cell lines tested.
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Figure 4 (A) 15-deoxy-PGJ2 inhibits phosphorylation and production of
Stat3 in oral SCCa cells. Oral SCC9 cells were treated with normal medium
(NM) or 20 mM 15-deoxy-PGJ2 for 45 min, or 1.5, 3, 4.5, 9, 24, 48, 72 h, as
indicated. Cells were lysed, blotted with antibody to phosphorylated Stat3
(phospho Stat3), and then sequentially stripped and reprobed with anti-
bodies to Stat3 and to actin. (B) 15-deoxy-PGJ2, but not rosiglitazone
or ciglitazone, inhibits phosphorylation and production of Stat3 in oral
SCCa cells. Oral SCCa cells, derived from cell lines SCC4, 15, or 25, were
treated for 48 h with normal medium (NM), 50 mM ciglitazone (CI), 50 mM
rosiglitazone (RO), or 20 mM 15-deoxy-PGJ2 (PG), as indicated. Cells
were lysed, blotted with antibody to phosphorylated Stat3 (phospho
Stat3), and then sequentially stripped and reprobed with antibodies to
Stat3 and to actin.
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tion has been suggested between PPARg and COX-2, which has
also been implicated in various human cancers, including head
and neck SCCa (Chan et al, 1999; Dannenberg et al, 2001). PPARg
activators may inhibit COX-2 expression, possibly through negative
interference with NF-kB and/or AP-1 activation (Inoue et al, 2000;
Subbaramaiah et al, 2001; Yang and Frucht, 2001). There is also
evidence that supports the function of PPARg ligands as potent
inhibitors of angiogenesis in vivo and in vitro, providing an addi-
tional mechanism that may partially account for the anticancer
properties of PPARg (Bishop-Bailey and Hla, 1999; Xin et al,
1999). Finally, cross-talk between PPARg and other signalling
molecules, such as NF-kB, AP-1 and STAT (Ricote et al, 1998;
Zhou and Waxman, 1999a,b), may contribute signiﬁcantly to the
effects of PPARg on tumour growth. The possible contribution,
if any, of PPARg activation to growth inhibition induced by 15-
PGJ2 treatment warrants further exploration.
Constitutive activation of Stat3 plays an important role in the
tumorigenesis of various types of human cancer (Catlett-Falcone
et al, 1999; Fernandes et al, 1999), and abrogation of Stat3 signal-
ling has been correlated with stimulation of cell proliferation,
prevention of apoptosis and tumour formation (Bromberg et al,
1999; Bowman et al, 2000). Based on accumulating evidence that
Stat3 is upregulated in head and neck SCCa (Grandis et al, 1998,
2000), we investigated whether treatment with PPARg ligands
exerts an effect on Stat3 protein expression and Stat3 tyrosine
phosphorylation. Treatment of oral SCCa cells with 15-PGJ2 at
concentrations that cause signiﬁcant reduction of cell growth
resulted in downregulation of both Stat3 expression and phosphor-
ylation. Given that targeting of Stat3 in head and neck SCCa has
been linked to signiﬁcant growth inhibition and induction of apop-
tosis both in vitro and in vivo (Grandis et al, 1998, 2000), our
results suggest that the ability of 15-PGJ2 to downregulate Stat3
may be aetiologically related to its growth inhibitory and apoptotic
effects. Interestingly, the mode of Stat3 downregulation (i.e. reduc-
tion of Stat3 phosphorylated levels after 45 min and elimination of
both Stat3 phosphorylated and unphosphorylated levels after 72 h)
was very similar to that induced by sulindac sulphide in the same
cell lines (Nikitakis et al, 2002b). Although sulindac’s growth inhi-
bitory effect was dependent on PPARg availability, its ability to
induce Stat3 downmodulation was independent of its ability to
act as a PPARg ligand. Similarly, the inability of PPARg activation
trough rosiglitizone and ciglitazone stimulation to affect the phos-
phorylation and expression levels of Stat3 entails that activation of
PPARg-independent mechanisms is necessary for 15-PGJ2-mediated
Stat3 downmodulation.
Both PPARg-dependent and PPARg-independent mechanisms
may come into play during Stat3 downregulation by 15-PGJ2.
Direct protein–protein interactions or indirect mechanisms, such
as competition for common co-activators or modulation of inhibi-
tors of transcriptional activity, have been suggested as possible
mediators of STAT-PPAR cross-talk and could account for the
Stat3 inhibitory effect of PPARg activation (Zhou and Waxman,
1999a,b). Cytokine stimulation results in phosphorylation of
STATs through the mediation of the Janus kinase (JAK) family
of protein tyrosine kinases (Darnell et al, 1994). Accordingly, the
recently proposed association between PPARg and cytokine expres-
sion may represent another possible connection between Stat3 and
PPARg. Indeed, PPARg agonists have been shown to suppress
monocyte elaboration of inﬂammatory cytokines (Jiang et al,
1998) and to inhibit IL-1b-induced expression of IL-8 in colon
cancer cell lines (Su et al, 1999). 15-PGJ2-mediated inhibition of
cytokine production and function may also ensue through
PPARg-independent pathways; for example, 15-PGJ2 has been
shown to modulate IL-1b effects in human chondrocytes (Boyault
et al, 2001) and to inhibit TNF-a and IL-6 production in human
macrophages without PPARg mediation. Inhibition of cytokine
expression by 15-PGJ2 would conceivably result in decreased acti-
vation of STAT molecules that mediate the transduction of the
cytokine signal from the cell surface to the nucleus. Head and neck
cancer cells have been shown to express a variety of pro-inﬂamma-
tory and pro-angiogenic cytokines (Chen et al, 1999; Ondrey et al,
1999) and to respond to IL-6 stimulation with upregulation of
Stat3 phosphorylation and promotion of cell growth; reversal of
this process could participate in the observed effects of 15-PGJ2
on oral SCCa cells. In that aberrant tumour growth factor-a/
epidermal growth factor receptor signalling has been demonstrated
to play a major role in Stat3 constitutive activation of head and
neck SCCa cells, possible interference of 15-PGJ2 with this path-
way, at the level of the ligand or the receptor, constitutes
another distinct possibility.
In summary, we demonstrated that 15-PGJ2, a speciﬁc natural
PPARg ligand, inhibits growth of oral SCCa cells, which may be
related to its capacity to downregulate the oncogene Stat3. The inef-
fectiveness of rosiglitazone and ciglitazone to cause similar effects
strongly suggests that 15-PGJ2 effects are at least partly mediated
through PPARg-independent mechanisms. Delineation of these
mechanisms, as well as determination of the potential contribution
of PPARg activation, not only will provide an explanation for 15-
PGJ2 anticancer qualities but it will also enhance our understanding
of critical signalling pathways for oral SCCa carcinogenesis.
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